Last reviewed · How we verify

NCT05551364

Usability and Effectiveness of the ATLAS2030 Exoskeleton in Children With Cerebral Palsy

Completed NA Last updated 27 September 2024
What this trial tests

NA trial testing ATLAS 2030 exoskeleton in Cerebral Palsy in 30 participants. Completed in 30 August 2023.

Timeline
5 September 2022
Primary endpoint
2 June 2023
30 August 2023

Quick facts

Lead sponsorMarsiBionics
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment30
Start date5 September 2022
Primary completion2 June 2023
Estimated completion30 August 2023
Sites6 locations across Spain

Drugs / interventions tested

Conditions studied

Sponsor

MarsiBionics

Who can join

Adults 3 to 14, any sex, with Cerebral Palsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this study is to assess the usability and efficacy of receiving therapy with the peaditric exoskeleton ATLAS 2030in children with gait impairment due to a cerebral palsy condition. It will be valued the impact of rehabilitation with the exoskeleton at the physical level on parameters such as joint range, spasticity, as well as the impact in quality of life. It is also assessed the impact at the level of functionality of the participants, through the administration of different functional assessment scales.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Benefits of robotic gait assistance with ATLAS 2030 in children with cerebral palsy.
    Castro P, Martí M, Oliván-Blázquez B, Boñar N, et al · · 2024 · cited 2× · PMID 39135857 · DOI 10.3389/fped.2024.1398044

Verify or expand the search:

Other recruiting trials for Cerebral Palsy

Currently open trials in the same condition.

Other MarsiBionics trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05551364.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing